OncoFrontier·Oct 26ESMO 2026: Blood Tests That Track Cancer Response Early, and What They Do Not Yet ProveEarly ctDNA results from ESMO 2026 show a blood test can track response, but it is not yet proven to guide treatment.
OncoFrontier·Oct 26A $192.5 Million Oncology Data Deal Shows What AI Runs On, and What It Does Not ProveTempus, Bristol Myers Squibb, and Pathos AI signed data agreements worth $192.5 million. It is a business deal, not clinical evidence.
OncoFrontier·Oct 22AI Reads DNA-Repair Clues From Ovarian Cancer Slides.A King’s College London model flags HRD in ovarian cancer from routine slides. Promising, but validation and better sensitivity are needed.
OncoFrontier·Oct 21AI Predicts Cancer Survival Risk From a Single Face Photo.A Mass General Brigham model links face photos to cancer survival risk. Experts ask what it sees and whether it adds to clinical judgement.
CancerFax - Advanced Cancer Treatment·Oct 8China’s ADC Moment: What the 2026 Lung Cancer Data Mean for PatientsTwo Chinese-discovered drugs just cut the risk of death in relapsed small cell lung cancer by more than half. Here is what that means, what…
OncoFrontier·Oct 6Oncology AI’s Next Hurdle: From Pilot to Routine, Safe Care by 2030A European strategy lab on October 5 asked what must change by 2030 for cancer AI to move from pilots to routine, safe, and scalable use.
CancerFax - Advanced Cancer Treatment·Oct 5When a disease is rare, the only option may be to treat it through a clinical trial.For most families living with a rare disease, the hardest sentence a doctor can say is not “this is serious.” It is “there is nothing…
CancerFax - Advanced Cancer Treatment·Oct 2Your Reports, Finally in Plain Language: What AI Can Really Do for Cancer PatientsA founder’s honest look at where artificial intelligence helps patients and families today and where it must stay quiet
CancerFax - Advanced Cancer Treatment·Oct 1For 13 Years, CAR-T Could Not Crack Solid Tumors. In 2026, China Approved the First OneSince the first CAR-T therapy was approved in 2017, every one that followed shared the same limit. They worked in blood cancers: leukemia…
CancerFax - Advanced Cancer Treatment·Sep 30Two Targets Instead of One: What Dual CAR-T Could Change in Blood CancerCAR-T cells have transformed leukemia, lymphoma, and myeloma care. Their biggest weakness is that cancer learns to hide. A new generation…
